Cases & Deals

Verastem develops global patent portfolio for COPIKTRA® (duvelisib)

Clients Verastem, Inc.

Jones Day represents Verastem, Inc. in the establishment of a global patent portfolio related to COPIKTRA® (duvelisib), a small molecule approved for the treatment of relapsed or refractory chronic lymphocytic leukemia ("CLL") or small lymphocytic lymphoma ("SLL") after at least two prior therapies and relapsed or refractory follicular lymphoma ("FL") after at least two prior systemic therapies.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.